The three peroxisome proliferator-activated receptors (PPAR) a, d (also called b, NUC-1 or FAAR) and g, which are all activated by naturally occurring fatty acids or fatty acid derivatives, constitute a distinct subfamily of the superfamily of nuclear receptors. They heterodimerize with retinoid X receptor (RXR) and change the transcription of numerous target genes after binding to specific response elements (PPREs), consisting of a direct repeat of the nuclear receptor hexameric DNA core recognition motif spaced by one nucleotide. Since they are activated by various fatty acid metabolites as well as several drugs used in the treatment of metabolic disorders, PPARs translate nutritional, pharmacological and metabolic stimuli into changes in the expression of genes. This review is focussed on the sexiest of the PPARs, i. e. PPARg, a claim mainly owing to its pivotal roles in adipogenesis and in insulin sensitization. Recently, a number of additional functions were attributed to PPARg, which suggested a more pleiotropic role affecting multiple fundamental pathways in the cell with wide-ranging bio-medical implications. Diabetologia (1999) 
For more general information relating to the other PPARs, I refer the reader to some general PPAR reviews for more exhaustive coverage [1, 2] .
The PPARg gene, RNA and protein
The human PPARg gene, which has nine exons and extends over more than 100 kb of genomic DNA [3] , is mapped to a locus on chromosome 3p25 in the proximity of the locus for RARb (3p24) and TRb (3p21) [4] . The gene is flanked by the polymorphic markers D3S1259 and D3S1286, which can be used in genetic association or linkage studies [5] . In contrast to mouse in which only two PPARg isoforms have been described so far [6] , in humans three PPARg mRNA isoforms have been identified, i. e. PPARg1, g2 [3] and g3 [7] (Fig. 1) . Alternate transcription start sites and alternate splicing generate the three PPARg mRNAs, which differ at their 5 ¢ ends ( Fig. 1) . Peroxisome proliferator-activated receptor is encoded by 8 exons whereas PPARg2 and g3 are each encoded by 7 exons. The 5 ¢ untranslated sequence of PPARg1 is comprised of exons A1 and A2 whereas that of PPARg3 contains only exon A2. The 5 ¢ untranslated sequence of PPARg2 plus the additional PPARg2-specific NH 2 -terminal amino acids are encoded by exon B, located between exons A2 and 1. The remaining 6 exons, termed 1 to 6, are common to the three PPARgs. Consistent with the production of three PPARg mRNAs, there are three PPARg promoters, with each a specific and distinctive expression pattern [3, 7] . Whereas the PPARg1 and g3 mRNAs give rise to an identical protein product, i. e. PPARg1, the PPARg2 mRNA encodes for the PPARg2 protein, which in man contains 28 additional amino acids encoded by the B exon.
As with all nuclear receptors, PPARg has a modular structure composed of several domains: the NH 2 -terminal A/B domain, harbouring a ligand-independent transcriptional activation function (AF-1); the C domain, which contains two zinc fingers, responsible for DNA binding; the D hinge region which is important for cofactor docking; and the EF COOH-terminal region, which among others contains the ligand-binding domain (LBD) and the ligand-dependent activation domain AF-2 [8] . The crystallographic structure of the LBD of PPARg has recently been determined by several groups by X-ray and was shown to have similar features to that of a number of the other nuclear receptors [9, 10] . In general, the unliganded (apo) LBD of a prototypical nuclear receptor is organized in 12 highly conserved a-helices which are folded into three layers to create a central hydrophobic ligand-binding pocket [9, 10] . The PPARg LBD is, however, somewhat different and contains one additional a-helix, termed helix 2 ¢, located between the b-strand and helix 3. The positioning of this helix 2 ¢ creates together with the changed tertiary placement of helix 2, a more accessible ligand-binding cavity, which is at approximately 1300 3 almost twice the size of that of other receptors (~600 3 ). Upon ligand binding, helix 12, which contains the conserved AF-2 core and in the unliganded receptor projects away from the LBD, reorientates and closes the ligand-binding pocket much like a lid on a pan [9] . This model, which is common for several nuclear receptors has been called the ªmouse trap modelº.
Little is known about the expression of PPARg during development in mammals but in Xenopus, unlike PPARa and b, PPARg expression is not detected during oogenesis [11] . In adult animals, PPARg expression is relatively confined. Adipose tissue, large intestine and haematopoietic cells express the highest levels of PPARg mRNA and protein, kidney, liver and small intestine have intermediate expressions whereas PPARg is barely detectable in muscle [3, 12] . Related to the subtype distribution, PPARg2 is much less abundant in all tissues analysed relative to PPARg1, the predominant PPARg form. The only tissue expressing pronounced amounts of PPARg2 is adipose tissue, in which PPARg2 mRNA makes up about 20 % of total PPARg mRNA [12] . The expression of PPARg3 mRNA is restricted to macrophages and the large intestine [7, 13] .
The expression of PPARg mRNA or protein or both in adipose tissue changes under the influence of a number of metabolic and hormonal variables. In humans short-term changes in food intake do not affect the expression of PPARg [12] , whereas hypocaloric diets for a longer period result in a down regulation of PPARg expression [14] . In rodents, PPARg was down regulated by fasting and insulin-dependent diabetes mellitus [15] whereas its expression was induced by a high-fat diet. Most interesting, however, was the observation, that in normal-weight subjects PPARg expression is highly enriched in subcutaneous fat, whereas its expression in visceral adipose tissue is statistically significantly higher in obese subjects [16] . Recently, we and others have shown that insulin induces PPARg expression rapidly in cultured human adipocytes [14, 17] whereas TNFa was reported to decrease PPARg expression [18, 19] . Furthermore it was shown that glucocorticoids could up-regulate PPARg expression in adipose tissue [14] .
Although expression of PPARg is low in muscle (less then 10 % of that in adipose tissue), a number of studies focussed on the regulation of PPARg expression in this tissue in view of its central role in glucose disposal [3] . Most studies show that PPARg1 is the predominant PPARg form [3, 20, 21] , and only one report showed the presence of PPARg2 [14] . In contrast to white adipose tissue, PPARg expression appears not to be regulated by insulin [20] . Obesity is associated with increased PPARg expression in the muscle [20] . Finally, a recent study suggests that both PPARg mRNA and protein are statistically significantly induced in muscle by treatment with PPARg agonists, suggesting a certain degree of transdifferentiation of the muscle cells [22] .
PPARg a coordinator for the thrifty response
Adipose tissue is composed of adipocytes, which store energy in the form of triglycerides during periods of nutritional abundance and release it as non-esterified fatty acids at times of nutritional deprivation [23, 24] . Excessive accumulation of adipose tissue leads to obesity whereas its absence is associated with lipodystrophic syndromes. The molecular mechanisms that control adipocyte differentiation from adipose precursor cells (adipoblasts) are complex and are affected by numerous signalling pathways. Although retroviral PPARg infection of fibroblast [25] and muscle [26] cells can induce adipocyte differentiation, this adipogenic property does not seem to be unique, since a whole range of transcription factors affect adipogenesis. It is currently thought that full-fledged adipogenesis requires an interplay between the PPARg/RXR heterodimer and two other groups of transcription factors: the CCAATT enhancer binding proteins (C/EBP) and adipocyte differentiation and determination factor 1/sterol regulatory element binding protein 1 (ADD-1/SREBP-1) (reviewed in [23, 24] ; Fig. 2 ). Although all of these transcription factors can independently induce adipocyte differentiation in vitro, they act synergistically in vivo. During the initial phases of adipogenesis C/EBPb and d are induced in response to adipogenic hormones such as insulin or glucocorticoids [27±29]. Both C/EBPs then induce the transcription of PPARg2, by interaction with a C/EBP site in the PPARg2 promoter. In its turn, PPARg2 then induces the expression of PPARg1 [30] . The obligate heterodimeric partner of PPARg, RXR constitutes another pivotal sensor during adipocyte differentiation [31] . On the direct repeat with one interspacing nucleotide (DR-1) response elements, such as most PPREs, RXR is a non-permissive inactive partner when heterodimerized with the peroxisome proliferator-activated receptor(RAR), whereas it is a permissive partner in the context of the PPARg/RXR heterodimer. The expressions of RAR and PPARg change considerably during the induction of adipocyte differentiation, with that of RAR being strongly reduced and of PPARg being induced [32] . A change in the relative expressions of RAR and PPARg in the differentiating adipocytes will hence induce a switch for RXR from one partner to another one [31, 32] . This will change RXR activity from the non-permissive state when bound to RAR to the permissive state when complexed to PPARg. This switch in partners induces the recruitment of a distinct set of cofactors, ultimately translating into an alteration of the transcriptional activity of the down-stream target genes ( Fig. 2) [31]. Such a switch might underly, not only how PPARg agonists but also, how RXR agonists exert their effects on adipogenesis and glucose homeostasis.
Another protein which is also induced early during adipocyte differentiation is the basic helix-loop-helix (bHLH) protein ADD-1/SREBP-1 [33, 34] . This transcription factor, which has a pivotal role in cholesterol homeostasis, also regulates the expression of several genes in fatty acid metabolism, and hence it has been suggested that ADD-1/SREBP-1 might control the generation of PPARg ligands which in their turn enhance the transcriptional activity of PPARg. Furthermore, recent work in our laboratory showed that ADD-1/SREBP-1, as well as the related bHLH factor, SREBP-2, can induce PPARg transcription through response elements in the PPARg1 and g3 promoter regions (Fajas and Auwerx, unpublished results). These interactions between cholesterol (ADD-1/SREBP) and fatty acid signalling (PPARg) point to an interplay of these two lipids in adipocyte biology. Finally, terminal adipocyte differentiation requires the concerted action of PPARg and C/EBPa [25, 26, 35] , another C/EBP family member which appears only relatively late in the differentiation process. Not only the expression of C/EBPa is controlled by PPARg but C/EBPa in its turn also induces PPARg gene expression through interaction with C/EBP response elements present in the human [30] and mouse [6, 35] PPARg promoter. This extensive cross-regulation between C/EBPs, PPARg/RXR and ADD-1/SREBP-1 is not only required to induce adipocyte differentiation but also to sustain the fully differentiated adipocyte phenotype.
The enhanced adipocyte differentiation, which ensues from PPARg activation, translates in the induction of the expression of adipocyte-specific genes. , who are all regulated by PPARg. The identification of PPREs in the LPL and ACS promoter and the induction of FATP-1 expression by PPARg ligands suggests that PPARg can also influence the generation and cellular uptake of its own ligands or activators. I suggest therefore that PPARg and its target genes have an interdependent role in adipocyte differentiation. This hypothesis is supported by the observation that fatty acids and fatty acid analogues induce the expression of adipocyte-specific genes, enhance adipocyte conversion and maintain the mature adipocyte phenotype by creating a positive feed-forward loop, which involves PPARg and several of its target genes (such as LPL, ACS, leptin, and FATP) [23, 24, 41] .
In addition to the genes already mentioned, which are mainly involved in adipocyte metabolism, two cytokines produced by the adipocytes, i. e. leptin and TNFa, also appear to be functioning in this adipocyte sustaining positive regulatory loop. Leptin is an adipocyte-derived signalling factor which, after interaction with specific cytokine-like receptors, induces a pleiotropic response including control of body weight and energy expenditure [42] . Leptin gene expression is regulated in an opposite fashion by PPARg and C/EBPa, the first one reducing its expression [48±50] and the second inducing its expression [46±48] . The decrease in circulating leptin concentrations after PPARg activation is associated with an increase in food intake, which provides substrates, subsequently to be stored in the adipocytes. A similar hypothesis can be formulated in relation to adipose tissue TNFa production. Tumour necrosis factor a, which was originally described as cachectin, is a potent inhibitor of adipocyte differentiation and exposure of . Hence, PPARg activation would not only favour adipocyte differentiation by affecting adipocyte metabolism, but in addition could also trigger an adipocyte-sustaining endocrine, paracrine or autocrine response consisting in decreased concentrations of two important adipocyte-derived signalling factors, leptin and TNFa. Therefore PPARg seems to be a master gene controlling a coordinated thrifty response.
Finally PPARg is not only a crucial element in the control of adipocyte differentiation but also in the modulation of programmed cell death in the adipocytes ([57], and J. Auwerx, unpublished results). Activation of PPARg has been shown to induce adipocyte apoptosis, mainly restricted to large fully differentiated adipocytes. This pro-apoptotic effect of PPARg activation on large adipocytes, coupled with its capacity to enhance differentiation of adipocytes de novo, favours the formation of small adipocytes which tend to replace the large adipocytes normally constituting white adipose tissue [57, 60] . It is therefore tempting to speculate that PPARg activation results in a continuous remodelling of adipose tissue (Fig. 3) . A hypothesis for the ultimate fate of these small freshly differentiated adipocytes that is worth exploring is that over time they store more and more energy and become hypertrophic and perhaps ultimately lead to a state of resistance to PPARg activation.
PPARg activation by insulin sensitizers underscores the importance of adipose tissue in insulin sensitivity
Like the other PPARs, PPARg, seems to be a very promiscuous receptor when it comes to activation, which can be achieved by a wide variety of naturally occurring and synthetic compounds. This property was shown to be linked to its spacious ligand-binding cavity [9, 10] . For some of these PPARg agonists, it was subsequently shown that they not only activate but also bind to the receptor. Naturally occurring arachidonic acid metabolites derived from the cyclooxygenase pathway, such as 15-deoxy-D12, 14-prostaglandin J2 [61±63] and D12-prostaglandin J2 [64] have received most attention. Although 15-deoxy-D12, 14-prostaglandin J2 was shown to be the most potent of the naturally occurring ligands with a high affinity for PPARg, it is still not clear whether it is produced in sufficient quantities in vivo. In contrast, D12-prostaglandin J2 has been shown to be made in vivo. A report that oestrogen induces the production of D12-prostaglandin J2 in duck uropygial gland should be noted in this context, since it points to cross-talk between oestrogen and peroxisome proliferator stimulated signalling pathways [64] is additionally supported by the recent observation that activation of RXR, the heterodimeric partner of PPARg, also induces adipocyte differentiation and improves glucose homeostasis [73] . These observations furthermore argue strongly that the active moiety involved in ameliorating glucose metabolism is the heterodimer PPAR/RXR.
Several recent studies point to the future bringing another dimension to the development of PPARg modulators, which until now was focussed on the development of simple agonists. Firstly, novel ligands, such as the thiazolidinediones derivative, KRP-297 and JTT-501, with activity towards both PPARa and g are being developed, widening both their tissuespecific activity and pharmacological properties [74, 75] . Treatment with a combination of compounds [76] or a single compound [80] with effects on both liver and adipose tissue can clearly enhance the therapeutic efficacy to restore complex metabolic disturbances, as seen in insulin resistance and Type II diabetes, to normal. Although little is known about their pharmacological properties, recently ligands able to bind and activate both PPARg and d have also been reported [77] . Secondly, the discovery of a novel thiazolidinedione, MCC-555, with appreciable anti-diabetic properties but only weak capacities to bind to PPARg, makes a notable exception to the rule that PPARg binding correlates with clinical efficacy [71, 72] . This thiazolidinedione can function either as a full or partial agonist or an antagonist depending on cell type and the sequence recognition site. This unique property can be explained by unique cofactor recruitment by this compound and indicates that it will be possible to produce tissue and promoter specific PPARg modulators.
The anti-diabetic effect of PPARg agonists, agents that induce adipocyte differentiation, might seem illogical since obesity, the end result of increased adipogenesis, is associated with insulin resistance. This discrepancy becomes apparent when one takes into account that on a whole body level, adipose tissue is absolutely required for glucose homeostasis in response to insulin. Subjects with lipoatrophy [78] and transgenic animals, which are engineered to lack adipose tissue, are extremely insulin resistant [79, 80] . This seems therefore to indicate that storage of energy reserves in the adipocytes favours insulin sensitivity and that the important adipogenic activity of PPARg contributes to the insulin sensitization of thiazolidinediones.
Although PPARg seems to have its primary effects on adipose tissue, it is not clear how PPARg agonists improve insulin sensitivity in muscle. Normally, adipose tissue (and liver) only contributes minimally ( < 10 %) to glucose disposal whereas muscle is responsible for most of the glucose uptake. Human muscle tissue, however, expresses only trace amounts of PPARg under basal conditions, making it ques- Fig. 3 . Remodelling of white adipose tissue by PPARg activation. Activation of PPARg in adipocytes will not only translate in apoptosis of the fully differentiated adipocytes but will also induce differentiation of preadipocytes de novo. This results in a continuous remodelling of the adipose tissue tionable whether muscle PPARg can account for the improvement in insulin sensitivity after treatment with thiazolidinediones. These minute quantities of PPARg in muscle might, however, be sufficient or alternatively might be induced during treatment with thiazolidinedione leading to an eventual direct PPARg-mediated response of the muscle to these insulin sensitizers. Alternatively, PPARg activators may generate an adipocyte-derived signal affecting insulin sensitivity in muscle. Both proteins and lipids have been proposed as non-mutually exclusive signalling molecules, which can affect the muscle. The prototypical examples of protein signalling molecules are the adipocytokines [81] . Tumour necrosis factor a is the prime example of molecules belonging to this group. Increased adipose tissue TNFa production has been shown to induce systemic insulin resistance by interference with the insulin signalling cascade [54, 55] . Thiazolidinediones have been shown to reduce TNFa expression, which may contribute to the improved insulin sensitivity [57, 58] . More recently, it was shown that leptin might also interfere with insulin signalling in vitro [82±84], although its in vivo activity on glucose homeostasis suggests otherwise [85] . In view of its interference with insulin signalling, reduced adipose tissue leptin production after thiazolidinediones [43±45] could potentially contribute in part to the improvement in insulin-stimulated glucose disposal. It is not known whether other adipocyte-derived proteins, such as adipsin [86] , angiotensinogen [87] , plasminogen activator inhibitor I [81] , and adipo Q [88, 89] , could also be involved in this signalling process. A second group of important mediators, which could affect insulin sensitivity in the muscle, consists of fatty acids. Since the original observation [90] , it has been well established that increased fatty acid concentrations decrease glucose metabolism in the muscle. Treatment with thiazolidinediones induces LPL, FATP-1, and ACS selectively in adipose tissue but they do not seem to change the expression of these genes in muscle tissue [91] . This might induce a ªfatty acid stealº due to a specific thiazolidinedione/PPARg-mediated increase in lipid and fatty acid clearance by adipose tissue, without a concomitant increase in fatty acid delivery to the muscle [92] . The resulting ªtrappingº of fatty acids in fat tissue could lead to a decreased systemic availability and a diminished fatty acid uptake by the muscle, potentially improving insulin sensitivity according to the mechanisms which have been proposed [90] .
Two additional points should be mentioned. Firstly, from all the above it is clear that the majority of PPARg regulated genes are involved in fatty acid or lipid metabolism or both and seem to be linked to adipocyte differentiation. In contrast, very little is known about regulation by PPARg of genes directly involved in glucose homeostasis. The mRNA encoding for the glucose transporter GLUT-4 was recently reported to be induced by PPARg. Similarly, it was shown that the c-Cbl associated protein (CAP) was induced by PPARg [93] . This protein, which is only expressed in cells that are metabolically sensitive to insulin, is involved in insulin-stimulated tyrosine phosphorylation of c-Cbl [93] . Secondly, it is important to stress that other adipose-independent mechanisms also contribute to the insulin-sensitizing effects of thiazolidinediones since these compounds retain this activity in transgenic mice that totally lack adipose tissue [94] . The exact nature of these non-adipose effects is, however, unclear and warrants more detailed investigation.
Genetic studies highlight the importance of ligand-independent activation and post-translational modification of PPARg Twin and family studies suggest that approximately 80 % of the variance in body mass index (BMI) is genetically determined [95] . Rare mutations in genes such as leptin or its receptor, controlling energy intake and expenditure, have been described in rodents [96, 97] and humans [98, 99] . Recently, mutations in PPARg have been described [5, 100±102], which in contrast to the above mutations presumably affect regulation of adipocyte differentiation and fat storage [5, 100±103]. A rare Pro115Gln mutation in the NH 2 -terminal ligand-independent activation domain of PPARg was found in four very obese subjects [100] . This mutation resulted in a permanently active PPARg since it inhibited phosphorylation of the protein at Ser114 and led to increased adipocyte differentiation capacity in vitro [100] . Furthermore, modification of the A/B domain by phosphorylation of this residue was reported to reduce ligand-binding affinity through interdomain communication between the A/B and the ligand-binding pocket in the DEF domain of PPARg. Phosphorylation at Ser114 was proposed as a mechanism by which growth factors and insulin, through mitogen-activated protein kinase, decrease PPARg activity and adipocyte differentiation (Fig. 4) [104±107].
We and others have recently described a much more common Pro12Ala substitution in the PPARg2-specific exon B [5, 101±103]. The PPARg2 Ala allele, whose frequency ranges from approximately 0.12 among Caucasians to 0.02 in Japanese Americans [101, 103] , was associated with lower BMI, improved insulin sensitivity and higher plasma HDL cholesterol concentrations [101] . The association with insulin sensitivity disappeared when corrected for BMI, indicating that the primary effect of this mutation was on body weight. Among JapaneseAmerican subjects, in whom the frequency of the PPARg Ala allele is much lower then in Caucasians, a statistically significantly lower frequency of the Ala allele among Type II diabetic subjects was observed relative to normal subjects. The PPARg Ala allele exhibited a reduced ability to transactivate responsive promoters. These results provide together with the observations made on the Pro115Gln substitution strong evidence of a role of PPARg in the control of adipogenesis in vivo, such that a more active PPARg (Pro115Gln) results in increased BMI [100] , whereas the opposite is seen with a less active PPARg (Pro12Ala) [101] . Further genetic support for a role of PPARg in the determination of body fat is that one of the loci with suggestive linkage to obesity (lod = 2.0) in Pima indians maps close to the location of PPARG in the 3p25-p24 region [108] .
These observations appear at odds with two reports which found no association of the Pro12Ala substitution with BMI and insulin sensitivity [102, 109] . In one study of 203 Japanese men, which included a total of only 12 carriers (1 homozygote and 11 heterozygotes) of the Ala allele, no correlations were observed with adiposity, fat distribution and insulin sensitivity [109] . The lack of association observed was most likely due to the limited number of carriers (n = 12) of the Ala allele in this population sample and to differences in diet between Japanese and Japanese Americans. The American diet has induced a higher frequency of insulin resistance and Type II diabetes among Japanese Americans [110] . In a second study involving 169 morbidly obese Caucasians, the Ala allele was associated with higher BMI [102] . These results suggest that the physiological consequences of the Pro12Ala polymorphism could be different in the lean and obese states. This is possibly due to the interaction of these isoforms of PPARg with metabolites or other regulatory proteins, the concentration of which may differ between obese and lean subjects. Consistent with this possibility is the recent findings in 1621 Danish males that the Ala allele could be associated with lower BMI among lean subjects and higher BMI among obese subjects [110 a]. These apparently conflicting results indicate the importance of gene environment interactions in the determination of the phenotype.
The genetic and functional data on the Pro12Ala substitution point to the importance of the PPARg2 specific B exon in determining the activity of PPARg more particularly in adipocytes, the only tissue known to express appreciable amounts of PPARg2. The exon B-encoded 28 NH 2 ±terminal residues were previously shown to be dispensable in in vitro assays of transcriptional activation and adipocyte differentiation [25] . In apparent contradiction to this observation, the NH 2 -terminus of PPARg2 was shown to be five to ten times more potent in transactivation assays than the NH 2 -terminus of PPARg1 [111] . The sequence of the first 13 of these 28 residues in PPARg2 is evolutionarily conserved between mouse, pig, cow and human, indicating that they are possibly functionally important in vivo (unpublished data and [3] ). The function of the NH 2 -terminal residues of PPARg2 is not known. This domain may modulate nuclear import, ligand binding, DNA binding, or transcriptional activation by inducing a conformational change, or it may endow PPARg2 with unique capacities to interact with co-activators or co-repressors that have been shown to interact with nuclear receptors. Support for the role of the NH 2 -terminus of PPARg in transcriptional activity not only comes from the presence of a ligand-independent AF-1 domain in this part of the molecule [111] but also from its allosteric effects on ligand-dependent transcriptional activity through interdomain communication [112] . The identification and characterization of proteins interacting with the NH 2 -terminus of PPARg in the future will point to mechanisms by which this domain affects adipose tissue accumulation and metabolism.
PPARg and the control of lipoprotein and extracellular lipid metabolism
In addition to its role in fat storage in the adipocytes, PPARg is also important in extracellular lipid metabolism, more particularly in that of triglyceride-rich lipoproteins [2, 8] . Steady state triglyceride concentrations are determined on the one hand by their production rates in the liver and gut, a process controlled to a large extent by substrate (fatty acid) availability and on the other hand by their clearance rate, a process under the control of LPL and apolipoprotein C-III. Activation of either PPARa or PPARg or both has pronounced triglyceride-lowering effects but the mechanisms by which they achieve this are largely different. Whereas thiazolidinediones predominantly affect triglyceride clearance, fibrates, which are weak PPARa ligands, exert their effects both on triglyceride clearance and production rates [8, 113] . Activation of PPARa reduces the production of apo C-III [114, 115] , whereas that of PPARg induces adipose tissue LPL gene expression [40, 76] , both resulting in a more efficient lipolysis-mediated clearance of triglycerides from the circulation. The induction of the LPL-mediated lipolysis of triglyceride-rich lipoproteins most likely underlies the increase in LDL particles often observed after the use of thiazolidinediones in animal models (such as the db/db mouse) or humans with increased concentrations of triglyceride-rich lipoproteins [116±119]. Further studies are necessary to establish whether this increased concentration of LDL particles is associated with an increased tendency to develop atherosclerosis.
The genetic studies discussed showed an association between the Pro12Ala substitution in the PPARg2 gene and increased HDL cholesterol and reduced total triglycerides concentrations [101] . The association of a less active PPARg variant with reduced triglyceride concentrations seems at odds with PPARg activation with synthetic ligands reducing triglyceride concentrations. A clear distinction needs, however, to be made between the general mild longterm modulating effect of mutations, mainly mediated by changes in adipose tissue mass and the more drastic and rapid changes in PPARg activity induced by pharmacological activation. The genetic association of HDL concentrations and PPARg2 Ala allele suggests that adipose tissue mass has important implications on reverse cholesterol transport [120, 121] . In addition, these genetic data support a role of adipose tissue in the complex lipid abnormalities associated with visceral obesity/insulin resistance syndrome, such as increased triglyceride and small dense LDL and low HDL concentrations.
More complexity; regulating PPARg activity through protein-protein interactions
Recently, a new functional class of proteins called ªcofactorsº were shown to play an important part in transcriptional control. Such cofactors also interact with nuclear receptors and they can either repress (corepressors) or enhance (coactivators) their transcriptional activities [122] . Initially it was thought that cofactors simply bridge transcription factors with the basic transcription machinery such as for p300, which is also a component of TATA-binding protein complexes [123] , or for the p300 homologous protein, CREB (cAMP-response element binding protein) binding protein (CBP), which has been shown to be associated with the RNA polymerase II by RNA helicase A [124] . Although this bridging function is important, several cofactors also have enzymatic activities, suggesting that they could control gene expression by specifically modifying chromatin and DNA structure. For instance, SUG-1 is a DNAhelicase [125] and transcription intermediary factor1a is a protein kinase [126] . Most notable, members of three groups of coactivators, i. e. the steroid receptor coactivator (SRC), CBP/p300, and the p300/CBP associated factor (p/CAF)/GCN family, can all acetylate histones [127±132] as well as other proteins of the transcription complex such as TFIIEb and TFIIF [133] . In contrast, the two corepressors silencing mediator for retinoid-hormone and thyroidhormone receptors (SMRT) and nuclear receptor corepressor , occur in a complex with histone deacetylase activity [134±136] . Histone hypoacetylation is associated with transcriptionally silent and condensed nucleosomes whereas acetylation is associated with increased transcription, suggesting that changes of nucleosome conformation modulate accessibility of promoter regions. Regulation of the acetylation of histones and of other DNA-binding proteins seems therefore to be of prime importance for transcriptional activation, which often occurs as a multistep process involving first removal of histone deacetylases from DNA with subsequent recruitment of histone acetyl transferases (Fig. 5) . In general, unactivated nuclear receptors are complexed with corepressors, which extinguish their transcriptional activity by the recruitment of histone deacetylases. Activation of the receptor then induces a conformational change which results in the dissociation of corepressors and the recruitment of coactivator complexes that contain proteins with histone acetyl transferase activity, which facilitates target gene transcription [122, 137] .
An important number of putative cofactors interact with the PPARs but a firm role in the regulation of the transcriptional activity of PPAR has not always been established. In the following section I will specifically focus on cofactors for PPARg, which have been shown not only to bind to but also to modulate its transcriptional activity. These include a silencing mediator for retinoid and thyroid hormone receptors (SMRT), a corepressor that inhibits RAR and thyroid hormone receptor-dependent transcription in the absence of their respective ligands and targets histone deacetylases to the DNA [138, 139] . In the presence of ligands, SMRT dissociates from these receptors allowing the recruitment of coactivators. It has been suggested that SMRT could also be involved in down-modulating PPARg-mediated gene transcription [140] . Indeed, EGF enhances the interaction of PPARg and SMRT in whole-cell extracts from CV-1 cells. Furthermore, antibodies directed against SMRT can relieve the mitogen activated protein kinase-dependent inhibition of the PPARg transcriptional activity [140] . Notably, microinjection of antibodies directed against SMRT was able to relieve SMRT corepression of PPAR's activity but antibodies directed against the related nuclear receptor corepressor were ineffective [140] . These data appear, however, at odds with the observation that PPARg seems to be capable of interacting with SMRT and nuclear receptor corepressor in solution only and not when bound as a heterodimer with RXR to its cognate response element [31, 141] . Furthermore, PPARs seem to be lacking the conserved receptor corepressor box [31] , previously found to be required for binding of corepressors to the receptors. These conflicting data therefore leave the question whether unliganded PPARg has any constitutive repressive activity on gene expression in vivo open.
Members of at least two families of histone acetylases, i. e. CBP/p300 and the SRC are reported to interact with PPARg. The first family, CBP and p300, are two related and widely expressed [142] cofactors that were originally identified as CREB [143] and E1 A [144] interacting factors [145] . They coactivate numerous transcription factors including several nuclear receptors [146±151] and were reported to have intrinsic histone acetyl transferase activity [127, 130, 132] . We have recently observed that CBP/p300 interacts with PPARg through multiple domains in each protein [152] . Most notably, the NH 2 -terminal region of PPARg can dimerize with CBP/p300 in the absence of ligand and this association enhances its constitutive AF-1 transcriptional activity [152] . The constitutive presence of cofactors such as CBP/p300 could hence enhance the basal ligand-independent transcriptional activity of PPARg in vivo and could together with the absence of well-documented interactions with corepressors explain the high basal activity of PPARg. A last point is that CBP/p300 seems to be able to contact other cofactors such as SRC-1 and its related family members [149] . This requires interactions of CBP/p300 with the consensus LXXLL motifs [153, 154] in SRC-1, each of which is sufficient for ligand-dependent interaction with nuclear receptors. This suggests that CBP/p300 could facilitate the assembly of multi-protein complexes involved in gene activation.
Steroid receptor coactivator was initially isolated as a progesterone receptor coactivator [155] but later was also shown to interact in a yeast two-hybrid system with the PPARg LBD [156] . Like CBP/p300, SRC-1 has an intrinsic histone acetyl transferase activity [131] and is ubiquitously expressed [142, 155] . It has a lower affinity for PPARg relative to CBP/ p300 [157] . It has been shown to have two PPARbinding domains, each containing LXXLL consensus receptor interaction motifs [153, 154] . Some residues COOH-terminal to LXXLL motifs are, however, also involved in receptor interaction [158] . The liganded PPARg LBD has been co-crystallized with a region of SRC-1 which contains two LXXLL motifs [9] . The structural data showed that the SRC-1 fragment interacted with two PPARg LBDs, with each of its LXXLL motifs contacting conserved residues in helix 12 (contains the AF-2) and 3 [9] . Mutation of the AF-2 is associated with a loss in transcriptional activity and a loss of capacity to interact with SRC-1 or CBP [157] .
Since both p300/CBP and SRC-1 are not specific for PPARg, several laboratories tried to identify PPARg-specific coactivators. Two coactivators, PPAR binding protein (PBP) [159] and PPAR gamma coactivator-1 (PGC-1) [160] , were isolated using this approach but they turned out not to be specific for PPARg. In addition, and in contrast to CBP/p300 and the SRC-1 families, it is not established whether these proteins contain any histone acetyl transferase activity. The first of these proteins isolated on the basis of its interaction with the LBD of PPARg in a yeast two-hybrid screen of a mouse liver cDNA library is PBP [159] . The PPARg and PBP are constitutively associated both in vitro and in vivo but the presence of a ligand reinforces this interaction. The PBP stimulates PPARg transcriptional activity only modestly but a truncated form bearing only the receptor-binding domain acts as a dominant-negative repressor, suggesting that PBP is a genuine coactivator for PPARg. It is expressed in a wide range of tissues, including several tissues where PPARg is of physiological importance such as adipose tissue, colon and breast [161] . The coactivator PGC-1 was isolated in a yeast two-hybrid screen of a mouse brown fat cell cDNA library [160] . It also turned out not to be specific for PPARg, since it also interacts with the thyroid hormone receptor. The interaction between PGC-1 and PPARg is ligand-independent both in vitro and in vivo. The PGC-1 is expressed in brown fat, heart, kidney and brain, all tissues where PPARg might be of physiological importance and its expression is induced by cold exposure in brown fat and skeletal muscle. When PGC-1 is ectopically expressed in white adipose cells, it activates expression of the uncoupling protein (UCP)-1, a key mitochon-drial enzyme of the respiratory chain, normally restricted in expression to brown adipose tissue. These observations suggest that PGC-1 could play a part in linking nuclear receptors to adaptive thermogenesis and indicate that it could be involved in the initiation of brown adipose tissue formation.
From this it is evident that although several cofactors interact with PPARg, none of these cofactors seem to be specific for PPARg. Understanding how these cofactor complexes interact and modulate receptor activity will require both detailed structural studies and the careful reconstitution of PPARg transcriptional activity in purified reconstituted transcription systems. Furthermore, several cofactors seem to be interacting as multiprotein complexes, suggesting a degree of redundancy. The recent observations made on the mode of action of the receptor interacting protein 140 (RIP140) suggest that some of them are mutually exclusive when interacting with the same receptor, pointing to the importance of the stoichiometry of the different components in the transcription complexes. Therefore it will also be of interest to better characterize the expression profiles of the various cofactors as well as to get more insight into the regulation of their respective promoters.
PPARg in inflammation and atherogenesis
Since fatty acid-derived signalling molecules are key components of several second messenger systems involved in the control of inflammation [162] , PPARg could serve as a tertiary messenger mediating certain of their transcriptional effects. The potential involvement of PPARg in inflammatory processes was first suggested by the general antagonism between the activities of the pro-inflammatory cytokine TNFa and PPARg, discussed above. Consistent with this antagonism between PPARg and cytokine production, were the observations that PPARg agonists seem to inhibit macrophage activation and limit the production of cytokines. Treatment of monocytes with either high doses of natural ligands or with synthetic PPARg agonists inhibits production of TNF-a, IL-1b and IL-6 [163] . Furthermore treatment with PPARg agonists induces a resting phenotype and down regulates the nitric oxide synthase [164, 165] , gelatinase B, and scavenger receptor A genes in the macrophage [164] . These processes seem to be mediated by a direct transcriptional effect of PPARg, which was suggested to interfere with the transcription factors nuclear factor (NF)-kB, activating protein 1 (AP)-1, and signal transducers and activators of transcription (STAT) all of which regulate cytokine gene expression [163, 164] . The potential weakness of these studies is that the cytokine modulation required concentrations of PPARg agonists far exceeding those necessary to activate PPARg, suggesting that other than PPARg additional pathways might be involved.
Another link between PPARg and inflammatory processes is that the natural PPARg ligands such as 15-deoxy-PGJ2 are products of the cyclooxygenase pathway, whose inhibition by NSAIDs constitutes a common treatment of inflammation. Evidence is accumulating that some of the actions of NSAIDs might not only be mediated through inhibition of cyclooxygenase but also through activation of PPARs. Some NSAIDs are direct activators of PPARg (and PPARa). The doses required for PPARg agonist activity are in the micromolar range, and exceed those required for in vivo inhibition of cyclooxygenases. High doses of these NSAIDs are often required, however, for adequate anti-inflammatory activity in vivo. It is therefore tempting to hypothesize that certain of the beneficial effects of NSAIDs are due to a PPARg-mediated suppression of cytokine synthesis.
This general anti-inflammatory role of PPARg is in contradiction with its function in macrophage foam cells, the initial abnormality in the early atherosclerotic lesions. The expression of PPARg is low in human peripheral blood monocytes [4] as well as in murine peritoneal [13] and lymph node macrophages [68] . Relative to undifferentiated resting monocytes, PPARg expression increases during macrophage dif- ferentiation induced by agents such as granulocyte macrophage-colony stimulating factor (GM-CSF), macrophage-colony stimulating factor (M-CSF), 1, 25-dihydroxyvitamin D3 or phorbol esters such as phorbol-myristate acetate [13, 68] . Likewise, activation of the PPARg/RXR heterodimer enhances macrophage differentiation [68] . Exposure of human monocytes or monocytic cell lines to oxidized LDL (oxLDL) but not regular LDL also induces PPARg expression [13, 68] . This in its turn stimulates the transcription of the oxLDL receptor CD36/fatty acid translocase (FAT) through a PPRE in the CD36/ FAT gene promoter thereby establishing a positive feed-forward loop leading to foam cell formation (Fig. 6) [68] . Exposure of monocyte/macrophages to oxLDL not only induces PPARg expression but provides the cells with two new PPARg ligands, i. e. 9-hydroxyoctadecadienoic and 13-hydroxyoctadecadienoic acids, both oxidative metabolites of linoleic acid present in oxLDL [67] . Consistent with this theory, high amounts of PPARg were observed in human [13, 166] and mouse [68] atherosclerotic lesions, where PPARg colocalized with oxLDL [13, 166] . The strong expression of PPARg in macrophage foam cells and atherosclerotic lesions as well as the important amounts of 9-hydroxyoctadecadienoic and 13-hydroxyoctadecadienoic acids present in oxLDL, suggest that such a mechanism could occur (Fig. 6) . These data suggest a complex function of PPARg in the macrophage and foam cell formation with a predominantly pro-atherogenic activity. This pro-atherogenic activity is possibly counterbalanced or neutralized by the effects of PPARg in vascular smooth muscle cells, where it inhibits the expression of matrix metalloprotease 9 and reduces cell migration induced by PDGF [167] . Further in vivo studies are, however, clearly necessary to define the exact role of PPARg in atherosclerotic plaque formation.
PPARg from a role in cell cycle to a role in cancer (Fig. 7) . Differentiation of preadipocytes into adipocytes cells occurs only after a prior and permanent exit from the cell cycle, consequent to changes in the activities of several factors involved in the regulation of the cell cycle [168] . Activation of PPARg seems to bypass the requirements of retinoblastoma protein for withdrawal from the cell cycle [169] . The DNA-binding and therefore the transcriptional activation properties of the cell growth promoting E2F/DP transcription factors is also inhibited after PPARg activation. This decrease in E2F/DP activity is due to an increased phosphorylation of these proteins, which results from the down-regulation of the PP2 A protein phosphatase expression [170] . This suggests that PPARg not only controls the expression of genes involved in the acquisition of a differentiated phenotype but also that PPARg plays an active part in the process of cell-cycle withdrawal. Furthermore, PPARg has been shown to drive the differentiation process of adipocytes and colon cells to its terminal point, i. e. apoptosis ([57] , and A.-M. Lefebvre andJ. Auwerx, unpublished results). In malignant cells from different lineages, such as liposarcoma [171] , human breast cancer [172, 173] , human colon cancer [174, 175] , and human prostate cancer cells [176] , PPARg ligands were also shown to inhibit growth and at least for breast and prostate cancer cells to induce apoptosis [172, 173] . This effect observed in vitro translates in vivo into a pronounced limitation of the proliferation of certain of these malignant cell lines in xenograft animal models. Consistent with this PPARg expression seems to be decreased in tumourigenic rodent mammary glands [176] . This led several groups to suggest that induction of terminal differentiation by PPARg agonists could represent a promising novel therapeutic approach for certain human malignancies.
In sharp contrast with these studies are the independent observations by two groups that activation of PPARg can promote the development of colon tumours in C57BL/6J-APC Min / + mice [177, 178] , a clinically relevant model for both human familial adenomatous polyposis and sporadic colon cancer [179±181]. Three observations led to the exploration of a potential role of PPARg in this model of colon carcinogenesis. Firstly, PPARg is highly expressed in the colon [3, 177, 182] . Secondly, the development of colorectal cancer is influenced by prostaglandins [183] . Decreased prostaglandin production, observed in mice with mutations in the cyclooxygenase 2 gene or in animals and humans treated with cyclooxygenase inhibitors, furthermore prevents or attenuates colon cancer development [184, 185] . Finally, there is a strong correlation between the intake of fatty acids from animal origin and colon cancer [186, 187] . Activation of PPARg by two different synthetic agonists increased the frequency and size of colon tumours in C57BL/6J-APC Min / + mice [177, 178] . Tumour frequency was only increased in the colon (by 425 % for rosiglitazone-treated and by 183 % for troglitazonetreated animals) whereas the frequency did not change in the small intestine, coinciding with the colon-restricted expression of PPARg. A similar increase in the frequency of colon tumours was observed previously when these mice were fed a diet high in saturated fats [187] , suggesting that PPARg could be involved in establishing the link between high-fat diet and colon cancer [186] . Treatment with PPARg agonists furthermore increased b-catenin concentrations both in the colon of C57BL/6J-APCMin / + mice and in HT-29 colon carcinoma cells [177] . Genetic abnormalities in the Wnt/wingless/APC pathway, which enhance the transcriptional activity of the b-catenin-Tcf/Lef1 transcription complex, have been shown to frequently underly the development of colon tumours.
These observations seem at odds with the above anti-proliferative properties associated with PPARg activation and the antitumourigenic effect of PPARg agonists on a xenograph model of colon cancer [188] . It is, however, most likely that the differences are mainly due to the differences in model systems used. The C57BL/6J-APC Min / + mice studies are an adequate model to study the effects of PPARg on the spontaneous development of colon cancers, whereas the xenograft model is better suited for studying the anti-proliferative capacity of PPARg activation in cancerous cells.
All these in vivo and in vitro data related to the effects of PPARg on cell cycle, apoptosis, and carcinogenesis definitely warrant follow-up. Careful monitoring of patients treated long-term with PPARg agonists is required. In addition, these data dictate the need for additional laboratory studies to address the role of PPARg in tumourigenesis. Finally, it will be of interest to evaluate a potential role of cofactors in these phenomena. Mutations or modulation in expression of coactivators or corepressors could be involved in PPARg-dependent tumour formation. A possible precedent for such a role of cofactors was highlighted by the increased expression of the coactivator amplified in breast cancer-1 (AIB-1), a member of the SRC-1 family, in breast cancer [189] .
Conclusions and perspectives
Although PPARg is one of the best characterized nuclear receptors, there are still enormous challenges ahead before modulators of this receptor can be recommended widely for long-term therapeutic use in metabolic disorders. As PPARg represents an important therapeutic target for the treatment of insulin resistance and Type II diabetes, a careful understanding of its exact role in physiology is an absolute requirement. This implies a detailed knowledge of all activities of PPARg, which are much broader than a strict function in adipose tissue. Most important is perhaps our need to understand the role of PPARg in the control of cell proliferation and differentiation. In addition, we need to identify novel ways to modulate PPARg activity without inducing unwanted side-effects such as the potential to enhance macrophage foam cell formation [13, 67, 68] , stimulate colon carcinogenesis [177, 178] , and induce acute liver dysfunction [190] . This will require thorough understanding about how this receptor interacts with cofactors and how it activates transcription. Furthermore, the restricted expression of certain PPARg isoforms, such as the adipose-restricted PPARg2 form, suggests the feasibility of the development of PPARg modulators affecting only one specific tissue, such as adipose tissue. All these developments will undoubtly facilitate the more rational design of new classes of PPARg modulators which might not be restricted to agonists but also include antagonists or inverse agonists, which could also have interesting therapeutic applications for the treatment of metabolic and eventually other diseases. 
